Mayo Clinic Researcher to Present Preclinical Findings for Aditxt's Immune Modulation Therapy

Aditxt Inc. will host a scientific update on May 2, 2025, featuring Dr. Charles Howe from Mayo Clinic, who will discuss critical findings from a preclinical study of ADI-100™, the lead therapeutic candidate from Aditxt's subsidiary, Adimune Inc.

The update will provide insights into the potential of ADI-100™, with additional perspectives from Aditxt's leadership, including Dr. Shahrokh Shabahang, Chief Innovation Officer, and Dr. Friedrich Kapp, Co-CEO of Adimune. The presentation represents a significant opportunity to understand emerging developments in immune modulation therapy.

This scientific presentation is part of Aditxt's broader strategy to advance innovative health solutions across multiple disciplines. The company is positioning itself as an innovation platform dedicated to addressing significant societal health challenges through collaborative research and development.

The preclinical study's findings could potentially offer new perspectives on immune health interventions, representing a promising step in understanding and potentially treating complex immune-related conditions. By bringing together experts from research institutions and industry, Aditxt aims to accelerate promising health innovations through a collaborative approach.